Xifaxan He denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for xifaxan he are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This as Duplicate Therapy

When Cigna issues a duplicate-therapy denial for rifaximin (Xifaxan) for hepatic encephalopathy (HE), it typically means their system has identified another medication already on file that they categorize as serving the same clinical purpose — often lactulose or another bowel-cleansing agent. The insurer's logic is that a second drug in the same therapeutic category is redundant unless clinical differentiation is documented.

This denial is frequently incorrect or incomplete because rifaximin for HE has a distinct pharmacologic profile and mechanism compared with osmotic agents, and your prescriber's clinical rationale for combining or substituting treatments may not have been communicated in the original authorization request.

## Why This Is Appealable

A duplicate-therapy determination is a coverage decision, not a clinical one, and it can be overturned when you demonstrate that the two treatments are not functionally interchangeable for your specific case. Federal rules give you concrete rights here:

• ACA §2719 / PHSA external review: If your plan is non-grandfathered, you can escalate to an independent external reviewer after exhausting internal appeals. You generally have approximately four months from the denial notice to request external review, though confirm the exact deadline on your Explanation of Benefits (EOB).
• ERISA §503 full-and-fair review: If your coverage is through an employer-sponsored plan, ERISA entitles you to a complete, impartial review of the denial and requires the plan to provide the specific clinical criteria used.
• Expedited review: If a standard timeline would seriously jeopardize your health, request expedited review at both the internal and external levels.

## Documentation to Gather

• Diagnosis confirmation: Records establishing your HE diagnosis and its severity, including any grading or staging documented in the chart.
• Prior-treatment history: Dates, doses, and outcomes for every HE-related treatment you have previously received, especially documentation of any inadequate response to or intolerance of the other agent Cigna identified as a duplicate.
• Clinical differentiation letter: A letter from your prescribing physician explaining — in specific clinical terms — why rifaximin is not duplicative in your case, citing your individual response history and the distinct mechanism of action relevant to your presentation.
• Prescriber's medical-necessity statement: A signed letter stating why rifaximin is medically necessary for you, referencing your diagnosis, disease course, and the applicable guideline organization (e.g., the relevant hepatology society guideline) without requiring you to cite specific numbers.

## Criteria-Mapping Approach

Obtain Cigna's published coverage policy for rifaximin-HE (available on Cigna's website under "Coverage Policies"). List every criterion the policy requires. For each criterion, pair it with the corresponding fact in your medical record — date of diagnosis, prior therapies tried, documented clinical response. This side-by-side mapping is the single most persuasive element of a successful appeal because it shows the reviewer exactly where the policy is satisfied.